Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07434479 · ClinicalTrials.gov registry record · NA
A Virtual Reality Mindfulness Application for Aggression in Schizophrenia
A NA study of Aggression and Schizophrenia Disorder, sponsored by Manhattan Psychiatric Center.
- Recruiting
- Registry status
- NA
- Development phase
- 58
- Enrollment target
- 2
- Study locations
NCT07434479: Recruiting NA study of Aggression and Schizophrenia Disorder, sponsored by Manhattan Psychiatric Center.
NCT07434479 is a NA study of Aggression and Schizophrenia Disorder that is actively recruiting participants, run by Manhattan Psychiatric Center. The registered enrollment target is 58 participants, below the 152-participant average among 21 other Aggression trials with a reported enrollment target (62% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07434479, a NA study of Aggression and Schizophrenia Disorder, is actively recruiting participants, sponsored by Manhattan Psychiatric Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 58 participants
- Enrollment target
- 2
- Study locations
Study Summary
The study investigates whether a virtual reality-based mindfulness based intervention can reduce impulsive aggression in individuals with schizophrenia or schizoaffective disorder. The primary goal is to evaluate whether mindfulness delivered via VR (MBI-VR) improves emotion regulation and engages the dorsomedial prefrontal cortex (dmPFC), a brain region involved in cognitive control and regulation of emotional responses. The study also examines whether these effects show a dose-related relationship. Participants will be randomized to receive different doses of MBI-VR intervention or distraction tasks and will complete repeated mindfulness VR sessions. Brain activity will be measured using functional magnetic resonance imaging (fMRI) during an emotion regulation task, along with clinical assessments of impulsive aggression related symptoms.
Primary Outcome
The Short UPPS-P is an instrument composed of 20 items rated on a four-point Likert scale: (1) disagree strongly, (2) disagree some, (3) agree some, and (4) agree strongly. Five scales were computed by adding the 4 items corresponding to each scale: (1) negative urgency (NU), the tendency to act impulsively when experiencing negative emotions (e.g., sadness, anger); (2) positive urgency (PU), the tendency to act rashly under extreme positive emotions or excitement; (3) sensation seeking (SS), th
Conditions Studied
Interventions
- OTHER Mindfulness-Based Virtual Reality Intervention
Study Locations (2)
New York
- Manhattan Psychiatric Center - New York
- NewYork-Presbyterian/Weill Cornell Medical Center Westchester Division - White Plains
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2026-03-02 |
| Est. Completion | 2027-12-31 |
| Phase | NA |
What NCT07434479 shows while recruiting
NCT07434479 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 152-participant average among 21 other Aggression trials with a reported enrollment target (62% lower).
The record links to 3 conditions, with Aggression appearing as the primary indexed condition, and to 1 intervention - of which Mindfulness-Based Virtual Reality Intervention is the first listed.
NCT07434479 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07434479 about?
NCT07434479 is a clinical study titled "A Virtual Reality Mindfulness Application for Aggression in Schizophrenia". The study investigates whether a virtual reality-based mindfulness based intervention can reduce impulsive aggression in individuals with schizophrenia or schizoaffective disorder. The primary goal is to evaluate whether mindfulness delivered via VR (MBI-VR) improves emotion regulation and engages t...
What is the current status of trial NCT07434479?
This trial is currently recruiting. It is a NA study. The enrollment target is 58 participants. The study started on 2026-03-02. Estimated completion is 2027-12-31.
What conditions does trial NCT07434479 study?
This clinical trial studies the following conditions: Aggression, Schizophrenia Disorder, Schizoaffecitve Disorder.
What interventions are being tested in trial NCT07434479?
The interventions under investigation include: Mindfulness-Based Virtual Reality Intervention (OTHER).
Who is sponsoring clinical trial NCT07434479?
This trial is sponsored by Manhattan Psychiatric Center, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07434479 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aggression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07434479's enrollment target sits among peer trials
58 12th of 21 higher than 10 of 21 other Aggression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Aggression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Manage Emotions to Reduce Aggression (MERA)
RECRUITING · NA
-
Manualized Assessment and Treatment Model of Challenging Behavior
RECRUITING · NA
-
Refinements of Functional Communication Training
RECRUITING · NA
-
Treatment of Chronic Anger and Aggression Following Military-Related Betrayal
RECRUITING · NA
-
Basic and Applied Research on Extinction Bursts
RECRUITING · NA
-
Just-In-Time Intervention to Reduce Alcohol-Facilitated Intimate Partner Violence Perpetration
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI